ScreenerHero

HBIO Harvard Bioscience, Inc.

NAS · US · Healthcare · Medical Instruments & Supplies · harvardbioscience.com
8.500USD-0.70%Mkt Cap: 38.69M $P/E: —

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offer…

Industry Peers

Medical Instruments & Supplies
Screen all
ISRG
Intuitive Surgical, Inc.
$146.44BUSDP/E 47.5
EL
EssilorLuxottica Société anonyme
$71.30BUSDP/E 26.7
BDX
Becton, Dickinson and Company
$49.07BUSDP/E 41.9
MDLN
Medline Inc.
$47.70BUSDP/E 88.6
RMD
ResMed Inc.
$31.78BUSDP/E 21.7
ALC
Alcon Inc.
$29.07BUSDP/E 50.2
ALC
Alcon Inc.
$30.45BUSDP/E 47.7
WST
West Pharmaceutical Services, Inc.
$25.79BUSDP/E 46.9
DIM
Sartorius Stedim Biotech S.A.
$22.00BUSDP/E 69.1
SRT3
Sartorius Aktiengesellschaft
$18.53BUSDP/E 87.2
STMN
Straumann Holding AG
$16.58BUSDP/E 39.4
SRT
Sartorius Aktiengesellschaft
$14.68BUSDP/E 69.1
SOLV
Solventum Corporation
$14.62BUSDP/E 10.5
BAX
Baxter International Inc.
$12.39BUSD
RGEN
Repligen Corporation
$10.62BUSDP/E 229.1
COO
The Cooper Companies, Inc.
$10.41BUSDP/E 18.8
AVTR
Avantor, Inc.
$10.38BUSD
COO
The Cooper Companies, Inc.
$10.29BUSDP/E 18.6
ALGN
Align Technology, Inc.
$9.94BUSDP/E 24.3
ATR
AptarGroup, Inc.
$7.66BUSDP/E 21.7
HeadlineSourceTime
Older
Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript

CRO demand drove 11% revenue growth, though margin pressures from China sales tempered gains.

Motley Fool
Harvard Bioscience, Inc. Q2 2026 Earnings Call Summary

Moby summary of Harvard Bioscience, Inc.'s Q2 2026 earnings call

Moby
Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights: Revenue Surges 11% and ...

Strong Q2 performance driven by robust demand in China and new product adoption, prompting an upward revision to full-year revenue growth outlook.

GuruFocus.com
Harvard Bioscience beats Q2 estimates and raises 2026 revenue guidance

Harvard Bioscience Inc. (NASDAQ:HBIO) reported better-than-expected second-quarter results on Tuesday and raised its full-year 2026 revenue outlook after stronger demand across its telemetry and cellular and molecular technology businesses.

InvestorsHub